AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29045323 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1341
Study 29045323 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE) program
Number of subjects: 1341
Study 25902885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (rosuvastatin 5 mg/day + ezetimibe 10 mg/day)
Number of subjects: 51
Study 25902885 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (rosuvastatin 5 mg/day)
Number of subjects: 51
Study 23597420 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 583
Study 23597420 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 583
Study 21718124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) training, 12 hours duration
Number of subjects: 272
Study 19700099 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary paclitaxel‐eluting stent implantation
Number of subjects: 0
Study 19700099 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous transluminal angioplasty (PTA)
Number of subjects: 0
Study 16720102 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance Feedback (PF) during MST and SST tests
Number of subjects: 40
Study 16720102 — intervention group
Group type: COMPARATOR
Intervention: Modified MST (MSTMD) with auditory feedback
Number of subjects: 40
Study 16720102 — intervention group
Group type: COMPARATOR
Intervention: Modified SST (SSTMD) with auditory feedback
Number of subjects: 40
Study 16720102 — intervention group
Group type: COMPARATOR
Intervention: Standard MST
Number of subjects: 40
Study 16720102 — intervention group
Group type: COMPARATOR
Intervention: Standard SST
Number of subjects: 40
Study 15261312 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 50
Study 15261312 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus remifentanil 0.1 microg/kg/min
Number of subjects: 50
Study 11748380 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of red ginseng powder per day for 5 years
Number of subjects: 300
Study 9624070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at home care
Number of subjects: 241
Study 9624070 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital care
Number of subjects: 241
Study 7946237 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterprise-based sheltered workshops
Number of subjects: 156
Study 3066849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioside GM1 (100 mg) given daily by intramuscular injection for 28 days
Number of subjects: 0
Study 3066849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29038069 — intervention group
Group type: EXPERIMENTAL
Intervention: Qsymia (phentermine/topiramate ER, 3.75mg/23mg-15mg/92mg)
Number of subjects: 30
Study 29038069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28092792 — intervention group
Group type: EXPERIMENTAL
Intervention: Curiosity
Number of subjects: 117
Study 24861411 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX) solution
Number of subjects: 44
Study 24861411 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine + 0.05% cetylpyridinium chloride (CPC) solution
Number of subjects: 44
Study 24171185 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐min repetitive experimental tooth‐clenching task (50% of maximal voluntary contraction)
Number of subjects: 30
Study 24171185 — intervention group
Group type: COMPARATOR
Intervention: Control session (no clenching)
Number of subjects: 30
Study 20724576 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab with CHOP-like chemotherapy
Number of subjects: 87
Study 20724576 — intervention group
Group type: COMPARATOR
Intervention: CHOP-like chemotherapy without rituximab
Number of subjects: 87
Study 19764187 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention including maintenance, protective equipment, procedures, training, health surveillance, fitness for work, first aid
Number of subjects: 612
Study 19764187 — intervention group
Group type: EXPERIMENTAL
Intervention: Health surveillance (HS)
Number of subjects: 612
Study 19764187 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety culture, behaviour and procedures
Number of subjects: 612
Study 16996347 — intervention group
Group type: EXPERIMENTAL
Intervention: Two bottles of NaP, 12 hours apart
Number of subjects: 200
Study 16996347 — intervention group
Group type: EXPERIMENTAL
Intervention: Two bottles of NaP, 24 hours apart
Number of subjects: 200
Study 16996347 — intervention group
Group type: COMPARATOR
Intervention: Two bottles of NaP, 6 hours apart
Number of subjects: 200
Study 16996347 — intervention group
Group type: COMPARATOR
Intervention: 4 L PEG
Number of subjects: 200
Study 15054570 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) 0 cm H(2)O
Number of subjects: 10
Study 15054570 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) 5 cm H(2)O
Number of subjects: 10
Study 15054570 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) 10 cm H(2)O
Number of subjects: 10
Study 11008905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysplastic nevi (DN)
Number of subjects: 20
Study 11008905 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nevi
Number of subjects: 20
Study 11008905 — intervention group
Group type: COMPARATOR
Intervention: Solar injury
Number of subjects: 20
Study 11008905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysplastic nevi (DN) without CDKN2A mutations
Number of subjects: 20
Study 11008905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysplastic nevi (DN) with CDKN2A mutations
Number of subjects: 20
Study 9278080 — intervention group
Group type: EXPERIMENTAL
Intervention: Active movement of the foot (maximum plantar flexion and dorsiflexion at 30 cycles per minute)
Number of subjects: 38
Study 9278080 — intervention group
Group type: COMPARATOR
Intervention: Control group (one minute of rest)
Number of subjects: 38
Study 7899391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg + placebo)
Number of subjects: 561
Study 7899391 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin (800 mg + placebo)
Number of subjects: 561
Study 2693915 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day of oral micronized E2 (n = 16)
Number of subjects: 32
Study 2693915 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-3 mg/day of percutaneous E2 (n = 16)
Number of subjects: 32
Study 302231 — intervention group
Group type: EXPERIMENTAL
Intervention: High power argon laser (6.5 +/- 1.0 w)
Number of subjects: 13
Study 302231 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power argon laser (1.0 +/- 0.1 w)
Number of subjects: 13
Study 302231 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 13
Study 302231 — intervention group
Group type: EXPERIMENTAL
Intervention: High power argon laser (Group B)
Number of subjects: 13
Study 302231 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (Group B)
Number of subjects: 13
Study 31727335 — intervention group
Group type: EXPERIMENTAL
Intervention: New surgical technique with oval window and stapes reinforcement
Number of subjects: 40
Study 31727335 — intervention group
Group type: COMPARATOR
Intervention: Original surgical technique with round window reinforcement
Number of subjects: 40
Study 31727335 — intervention group
Group type: EXPERIMENTAL
Intervention: New surgical technique
Number of subjects: 40
Study 30908363 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative telephone follow-up (TFU)
Number of subjects: 104
Study 30908363 — intervention group
Group type: COMPARATOR
Intervention: No postoperative telephone follow-up (no TFU)
Number of subjects: 104
Study 28078090 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote physical activity monitoring and feedback (RAMF)
Number of subjects: 150
Study 28078090 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling (TC)
Number of subjects: 150
Study 28078090 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 28078090 — intervention group
Group type: EXPERIMENTAL
Intervention: RAMF
Number of subjects: 150
Study 28078090 — intervention group
Group type: EXPERIMENTAL
Intervention: TC
Number of subjects: 150
Study 26466483 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) with mixed particles graft
Number of subjects: 67
Study 26466483 — intervention group
Group type: COMPARATOR
Intervention: Mixed particles graft (control group)
Number of subjects: 67
Study 24206747 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L of PEG3350e with 15 mg bisacodyl
Number of subjects: 325
Study 24206747 — intervention group
Group type: COMPARATOR
Intervention: 4 L of PEG3350e
Number of subjects: 325
Study 22117606 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg once daily for 4 days starting preoperatively)
Number of subjects: 100
Study 22117606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsule)
Number of subjects: 100
Study 22117606 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 100
Study 22117606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20855049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 48
Study 20855049 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 48
Study 17717203 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC)
Number of subjects: 158
Study 17717203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 15567545 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower group during sit to stand task
Number of subjects: 41
Study 15567545 — intervention group
Group type: COMPARATOR
Intervention: Fast group during sit to stand task
Number of subjects: 41
Study 15567545 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower group
Number of subjects: 41
Study 12200601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free effusions after exposure in malignant cases
Number of subjects: 123
Study 12200601 — intervention group
Group type: COMPARATOR
Intervention: Non-malignant effusions
Number of subjects: 123
Study 12200601 — intervention group
Group type: EXPERIMENTAL
Intervention: EAL cells in malignant effusions
Number of subjects: 123
Study 12200601 — intervention group
Group type: EXPERIMENTAL
Intervention: EAL cells in infected effusions
Number of subjects: 123
Study 12200601 — intervention group
Group type: EXPERIMENTAL
Intervention: sHLA-I levels in malignant effusions
Number of subjects: 123
Study 12200601 — intervention group
Group type: EXPERIMENTAL
Intervention: sHLA-I levels in infected patients
Number of subjects: 123
Study 12200601 — intervention group
Group type: EXPERIMENTAL
Intervention: sHLA-I levels in other diseases
Number of subjects: 123
Study 9704777 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin gene expression in tissues from patients with preterm premature rupture of the membranes
Number of subjects: 34
Study 9704777 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 gene expression in severely infected tissues
Number of subjects: 34
Study 9704777 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1beta and interleukin-8 gene expression in severely infected tissues
Number of subjects: 34
Study 8730886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine growth restriction (IUGR) group
Number of subjects: 13
Study 8730886 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 1726988 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/kg b.w. per minute for 3 hours)
Number of subjects: 24
Study 1726988 — intervention group
Group type: EXPERIMENTAL
Intervention: OKY‐046 (400 mg single oral dose)
Number of subjects: 24
Study 7086586 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine-restricted diet continued
Number of subjects: 115
Study 7086586 — intervention group
Group type: COMPARATOR
Intervention: Phenylalanine-restricted diet discontinued
Number of subjects: 115
Study 31465757 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchor system intervention
Number of subjects: 42
Study 31465757 — intervention group
Group type: COMPARATOR
Intervention: No anchor system intervention
Number of subjects: 42
Study 31465757 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 42
Study 30913164 — intervention group
Group type: EXPERIMENTAL
Intervention: mirogabalin 15 mg/day
Number of subjects: 765
Study 30913164 — intervention group
Group type: EXPERIMENTAL
Intervention: mirogabalin 20 mg/day
Number of subjects: 765
Study 30913164 — intervention group
Group type: EXPERIMENTAL
Intervention: mirogabalin 30 mg/day
Number of subjects: 765
Study 30913164 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 765
Study 28350787 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI+5-FU/LV
Number of subjects: 236
Study 28350787 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 236
Study 25247433 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 83
Study 25247433 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 83
Study 23558372 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection through a common paraneural sheath
Number of subjects: 89
Study 23558372 — intervention group
Group type: COMPARATOR
Intervention: Conventional postbifurcation injection external to the paraneural tissue
Number of subjects: 89
Study 21499200 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg acetylsalicylic acid
Number of subjects: 36
Study 21499200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19730367 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking dose of alcohol
Number of subjects: 428
Study 19730367 — intervention group
Group type: COMPARATOR
Intervention: Non-binge drinkers receiving an equivalent dose of alcohol
Number of subjects: 428
Study 16325937 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral care
Number of subjects: 190
Study 14764947 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion during ITT
Number of subjects: 8
Study 14764947 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control test)
Number of subjects: 8
Study 14764947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose infusion during ITT
Number of subjects: 8
Study 11244389 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 10) exposed to dirty glasses
Number of subjects: 20
Study 11244389 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10) exposed to neutral slides and objects
Number of subjects: 20
Study 11244389 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 10)
Number of subjects: 20
Study 11244389 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 20
Study 1466329 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (400 mg/day)
Number of subjects: 87
Study 1466329 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxepa (10 g/day)
Number of subjects: 87
Study 6706275 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of codeine and paracetamol
Number of subjects: 12
Study 6706275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of codeine and paracetamol
Number of subjects: 12
Study 31690051 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 = 0.80
Number of subjects: 0
Study 31690051 — intervention group
Group type: COMPARATOR
Intervention: FiO2 = 0.40
Number of subjects: 0
Study 27933715 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective Continuous Glucose Monitoring (CGM)
Number of subjects: 30
Study 27933715 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 30
Study 27933715 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 30
Study 27940713 — intervention group
Group type: EXPERIMENTAL
Intervention: Food advertisements
Number of subjects: 60
Study 27940713 — intervention group
Group type: COMPARATOR
Intervention: Nonfood advertisements (Control)
Number of subjects: 60
Study 25517808 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice about smoking cessation given at the start of anti-tuberculosis treatment, repeated 2 and 5 months later.
Number of subjects: 246
Study 25517808 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention.
Number of subjects: 246
Study 22710067 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor training (playing Guitar Hero 2h/day with the nondominant hand)
Number of subjects: 9
Study 22710067 — intervention group
Group type: COMPARATOR
Intervention: Immobilization (wearing an immobilization splint 24h/day)
Number of subjects: 9
Study 22710067 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor training
Number of subjects: 9
Study 22710067 — intervention group
Group type: COMPARATOR
Intervention: Immobilization
Number of subjects: 9
Study 19326270 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief school-based selective prevention program
Number of subjects: 47
Study 19326270 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WLC)
Number of subjects: 47
Study 19326270 — intervention group
Group type: COMPARATOR
Intervention: Normal control (NC)
Number of subjects: 47
Study 18429579 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on rates of live donor kidney transplantation
Number of subjects: 132
Study 15977735 — intervention group
Group type: EXPERIMENTAL
Intervention: WT-FD filter
Number of subjects: 0
Study 12870368 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 376
Study 12870368 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil 500 mg twice daily for 10 days
Number of subjects: 376
Study 10598299 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 10598299 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0
Study 8694150 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate 0.3 M, 30 ml (group C)
Number of subjects: 384
Study 8694150 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg IV + Sodium citrate (group MC)
Number of subjects: 384
Study 8694150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate + Ranitidine 50 mg IV (group RC)
Number of subjects: 384
Study 8694150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate + Omeprazole 40 mg IV (group OC)
Number of subjects: 384
Study 8694150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate + Ranitidine 50 mg + Metoclopramide 10 mg (group RMC)
Number of subjects: 384
Study 8694150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate + Omeprazole 40 mg + Metoclopramide 10 mg (group OMC)
Number of subjects: 384
Study 8694150 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate (group C and MC)
Number of subjects: 384
Study 8694150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate + Ranitidine, Omeprazole, or Metoclopramide (groups OC, RC, OMC, RMC)
Number of subjects: 384
Study 1912918 — intervention group
Group type: EXPERIMENTAL
Intervention: Single postprandial test
Number of subjects: 2984
Study 1912918 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprandial and postprandial tests
Number of subjects: 2984
Study 1912918 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening cost
Number of subjects: 2984
Study 1912918 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously undiagnosed diabetes
Number of subjects: 2984
Study 2868744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol (50, 100, 200 and 400 mg)
Number of subjects: 12
Study 2868744 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg)
Number of subjects: 12
Study 2868744 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg)
Number of subjects: 12
Study 2868744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol (200 and 400 mg)
Number of subjects: 12
Study 2868744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol (200 mg)
Number of subjects: 12
Study 2868744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol (400 mg)
Number of subjects: 12
Study 2868744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 12
Study 29673735 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug therapy (TDT) with albendazole (400 mg), pyrantel pamoate (20 mg/kg), and oxantel pamoate
Number of subjects: 414
Study 29673735 — intervention group
Group type: COMPARATOR
Intervention: Albendazole plus oxantel pamoate
Number of subjects: 414
Study 29673735 — intervention group
Group type: COMPARATOR
Intervention: Pyrantel pamoate plus oxantel pamoate
Number of subjects: 414
Study 29673735 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug therapy (TDT) with albendazole, pyrantel pamoate, and oxantel pamoate
Number of subjects: 414
Study 29673735 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 414
Study 27378162 — intervention group
Group type: EXPERIMENTAL
Intervention: Large group size (median 8 students)
Number of subjects: 115
Study 27378162 — intervention group
Group type: COMPARATOR
Intervention: Standard group size (median 4 students)
Number of subjects: 115
Study 24275262 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed sutures
Number of subjects: 34
Study 24275262 — intervention group
Group type: COMPARATOR
Intervention: Traditional sutures
Number of subjects: 34
Study 23984599 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional abdominal pain
Number of subjects: 96
Study 23984599 — intervention group
Group type: EXPERIMENTAL
Intervention: Irritable bowel syndrome
Number of subjects: 96
Study 23984599 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 96
Study 21653578 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions linking temptation to dieting goal
Number of subjects: 0
Study 21653578 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0